These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7367824)

  • 1. Functioning liver mass in uncomplicated and fulminant acute hepatitis.
    Ramsøe K; Andreasen PB; Ranek L
    Scand J Gastroenterol; 1980; 15(1):65-72. PubMed ID: 7367824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholic acid conjugation test and quantitative liver function in acute liver failure.
    Bremmelgaard A; Ranek L; Bahnsen M; Andreasen PB; Christensen E
    Scand J Gastroenterol; 1983 Sep; 18(6):797-802. PubMed ID: 6669944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure.
    Ranek L; Andreasen PB; Tygstrup N
    Gut; 1976 Dec; 17(12):959-64. PubMed ID: 1017716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of plasma fibronectin in fulminant hepatitis: association with infection and mortality.
    Acharya SK; Dasarathy S; Irshad M
    J Hepatol; 1995 Jul; 23(1):8-13. PubMed ID: 8530814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prognostic markers for fatal fulminant hepatic failure cases with viral hepatitis: proton nuclear magnetic resonance spectroscopic studies of serum.
    Bala L; Mehrotra M; Mohindra S; Saxena R; Khetrapal CL
    Dig Liver Dis; 2013 Feb; 45(2):155-63. PubMed ID: 23122710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.
    Miyake Y; Iwasaki Y; Terada R; Onishi T; Okamoto R; Sakai N; Sakaguchi K; Shiratori Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1347-53. PubMed ID: 16629940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of fatality in fulminant hepatic failure.
    Christensen E; Bremmelgaard A; Bahnsen M; Andreasen PB; Tygstrup N
    Scand J Gastroenterol; 1984 Jan; 19(1):90-6. PubMed ID: 6538698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis.
    Shiota G; Oyama K; Noguchi N; Takano Y; Kitaoka S; Kawasaki H
    Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):3-12. PubMed ID: 9755839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecstasy induced acute hepatic failure. Case reports.
    Atayan Y; Çağın YF; Erdoğan MA; Harputluoglu MM; Bilgic Y
    Acta Gastroenterol Belg; 2015; 78(1):53-5. PubMed ID: 26118578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulminant hepatitis: Mayo Clinic experience with 34 cases.
    Rakela J; Lange SM; Ludwig J; Baldus WP
    Mayo Clin Proc; 1985 May; 60(5):289-92. PubMed ID: 3921780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase ratio as a prognostic index in severe acute viral hepatitis.
    Gitlin N
    Am J Gastroenterol; 1982 Jan; 77(1):2-4. PubMed ID: 6801971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential evaluation of portal venous hemodynamics by Doppler ultrasound in patients with severe acute hepatitis.
    Tai D; Changchien CS; Chen CJ; Chiou SS; Lee CM; Kuo CH; Chen JJ; Chiu KW; Chuah SK; Hu TH
    Am J Gastroenterol; 1996 Mar; 91(3):545-50. PubMed ID: 8633506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of non A, non B, non C hepatitis that relapsed into fulminant hepatic failure.
    Cuffari C; Brochu P; Russo P; Alvarez F
    Hepatogastroenterology; 1998; 45(24):2348-51. PubMed ID: 9951921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum glycoproteins in the liver diseases. III. Desialylated glycoproteins in the acute hepatitis.
    Arima T; Motoyama Y; Yamamoto T; Nagata K; Kondo T
    Gastroenterol Jpn; 1977; 12(2):39-42. PubMed ID: 892334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenazone metabolism in patients with liver disease.
    Andreasen PB; Greisen G
    Eur J Clin Invest; 1976 Jan; 6(1):21-6. PubMed ID: 1253807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilirubin or plasminogen--which is better in the assessment of the severity of viral hepatitis?
    Boyadjian HP
    Gastroenterol J; 1991; 51(2):56-61. PubMed ID: 1755947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation.
    Takahashi Y; Kumada H; Shimizu M; Tanikawa K; Kumashiro R; Omata M; Ehata T; Tsuji T; Ukida M; Yasunaga M
    Hepatology; 1994 May; 19(5):1065-71. PubMed ID: 8175127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnosis and management of viral hepatitis.
    Main J; Jacyna MR; Thomas HC
    Commun Dis Rep CDR Rev; 1992 Sep; 2(10):R117-20. PubMed ID: 1284927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
    Tillmann HL; Hadem J; Leifeld L; Zachou K; Canbay A; Eisenbach C; Graziadei I; Encke J; Schmidt H; Vogel W; Schneider A; Spengler U; Gerken G; Dalekos GN; Wedemeyer H; Manns MP
    J Viral Hepat; 2006 Apr; 13(4):256-63. PubMed ID: 16611192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon treatment in acute progressive and fulminant hepatitis.
    Levin S; Leibowitz E; Torten J; Hahn T
    Isr J Med Sci; 1989 Jul; 25(7):364-72. PubMed ID: 2474521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.